Floatz logo

Carboplatin

Advanced KRAS G12D Mutant Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.Small moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Advanced KRAS G12D Mutant Solid Tumors cohort.

Asset / SponsorPhaseRating
Hrs-4642
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
ETOPOSIDE
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Cetuximab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Shr-9839
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Adebrelimab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Hrs-6093
Jiangsu HengRui Medicine Co., Ltd.
Phase 1CC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →